PubMed Health⌕ Search

Biomedical subjects

M Rørth

Publications and source records attributed to M Rørth.

117 records · Page 7Linked to original sources
PubMed1982

Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.

The antineoplastic activity of vindesine was evaluated in a phase II trial in patients with squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung. Sixty-three patients participated in the trial: 22 with squamous cell carcinoma, 25 with adenocarcinoma, and 16 with large cell carcinoma. Most of the patients had not received prior treatment; six had received single-agent chemotherapy. The dose of vindesine was 4 mg/m2 every 2 weeks, reduced or increased according to hematologic and neurologic side effects. Fifty-four patients were evaluable. Objective response was observed in two of 19 patients with squamous cell carcinoma (11%), in six of 22 patients with adenocarcinoma (27%), and in one of 13 patients with large cell carcinoma (8%). In patients with adenocarcinoma the median duration of response was 196 days (range, 71-450+). Twenty-five percent of the evaluable patients received greater than or equal to 100% of the scheduled dose. In 39% of the patients, dose reductions were necessary because of leukopenia, and in 63%, dose modifications were necessary because of neurotoxic effects. It is concluded that vindesine as a single-agent chemotherapy is active against adenocarcinoma of the lung. Activity in squamous cell carcinoma and large cell carcinoma appears to be less, but not totally absent.

Adenocarcinoma↗
PubMed1981

Selection of high risk groups among prognostically favorable patients with breast cancer.

In a prospective, nationwide, decentralized breast cancer project conducted by The Danish Breast Cancer Cooperative Group (DBCG) the recurrence rate within the first year after surgery was analysed in relation to tumor anaplasia. One thousand forty-eight patients met the requirements of eligibility, i.e. tumor size less than or equal to 5 cm with negative axillary nodes, and no skin or deep invasion. The recurrence rates in tumors with anaplasia Grades I, II, and III were 4, 9, and 14%, respectively (p = 0.001). Therefore, it seems possible, prospectively, among otherwise prognostically favorable patients, to select a group with high risk of recurrence which might benefit from adjuvant systemic therapy.

Anaplasia↗
PubMed1979

Red cell 2.3-diphosphoglycerate in pregnancy.

In normal, primigravidae red cell 2.3-diphosphoglycerate (2.3-DPG) concentration was found to be increased significantly from the third month of pregnancy. The 2.3-DPG concentration remained elevated throughout pregnancy. Increase in the 2.3-DPG concentration leads to a decrease in the oxygen affinity of the maternal red cells. The combination of low pCO2 and low oxygen affinity of the maternal blood facilitates the transport of oxygen as well as that of carbon dioxide across the placenta. The weight of the delivered children was not significantly correlated to the 2.3-DPG changes, and no significant variation of the measured variables could be detected in 9 women with abnormal pregnancies.

Adult↗
PubMedDate not supplied

5-FU in the treatment of small cell anaplastic carcinoma of the lung: a phase II trial.

The effect of 5-FU as a single agent in small cell anaplastic carcinoma of the lung was evaluated in 26 patients. All patients had received prior chemotherapy. Ten patients were treated with 5-FU doses of 600 mg/m2 iv on Days 1--5, followed by 1000 mg/m2 iv on Day 22 and then every second week. Among eight evaluable patients, partial remissions of 42--45 days' duration were seen in three cases. However, toxic reactions, consisting of thrombocytopenia (less than 50,000/mm3) in five cases and leukopenia (less than 1000/mm3) with septicemia in two patients, were unacceptable. Therefore, the remaining 16 patients were treated with 400 mg/m2 iv daily for 5 days, while the maintenance dosage of 5-FU remained unchanged. With this dosage the hematologic toxicity was moderate, but no responses were observed. It is concluded that 5-FU has a low order of activity in previously treated patients with small cell anaplastic carcinoma of the lung.

Aged↗